Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 332

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia

Krauss, Aviva C., Gao, Xin, Li, Liang, Manning, Michael L., Patel, Paresma, Fu, Wentao, Janoria, Kumar G., Gieser, Gerlie, Bateman, David A., Przepiorka, Donna, Shen, Yuan Li, Shord, Stacy S., Sheth, Christopher M., Banerjee, Anamitro, Liu, Jiang, Goldberg, Kirsten B., Farrell, Ann T., Blumenthal, Gideon M., Pazdur, Richard·2019·Clinical Cancer Research

Abstract

On August 3, 2017, the FDA granted regular approval to Vyxeos (also known as CPX-351; Jazz Pharmaceuticals), a liposomal formulation of daunorubicin and cytarabine in a fixed combination, for the treatment of adults with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or acute myeloid leukemia (AML) with myelodysplasia-related changes (AML-MRC). Approval was based on data from Study CLTR0310-301, a randomized, multicenter, open-label, active-controlled trial comparing Vyxeos with a standard combination of daunorubicin and cytarabine (“7+3”) in 309 patients 60–75 years of age with newly diagnosed t-AML or AML-MRC. Because of elemental copper concerns with the Vyxeos formulation, patients with Wilson disease were excluded from the study. Vyxeos demonstrated an improvement in overall survival (HR 0.69; 95% confidence interval, 0.52–0.90; P = 0.005) with an estimated median overall survival of 9.6 months compared with 5.9 months for the “7+3” control arm. The toxicity profile of Vyxeos was similar to that seen with standard “7+3” with the exception of more prolonged neutropenia and thrombocytopenia on the Vyxeos arm. Because the pharmacology of Vyxeos differs from that of other formulations of daunorubicin and cytarabine, labeling includes a warning against interchanging formulations during treatment. This is the first FDA-approved treatment specifically for patients with t-AML or AML-MRC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-18-2990

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 332

Metadata

Authors
Krauss, A. C., Gao, X., Li, L., Manning, M. L., Patel, P., Fu, W., Janoria, K. G., Gieser, G., Bateman, D. A., Przepiorka, D., Shen, Y. L., Shord, S. S., Sheth, C. M., Banerjee, A., Liu, J., Goldberg, K. B., Farrell, A. T., Blumenthal, G. M., & Pazdur, R.
Venue
Clinical Cancer Research
Published
2019-05-01
Volume
25
Issue
9
Pages
2685-2690
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2905340197
Cited by
332
References
12
FWCI
18.84
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-18-2990
The paper
Krauss, A. C., Gao, X., Li, L., Manning, M. L., Patel, P., Fu, W., Janoria, K. G., Gieser, G., Bateman, D. A., Przepiorka, D., Shen, Y. L., Shord, S. S., Sheth, C. M., Banerjee, A., Liu, J., Goldberg, K. B., Farrell, A. T., Blumenthal, G. M., & Pazdur, R. (2019). FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-18-2990

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.